As a research-based organisation, it is of paramount importance that there is reliable scientific evidence to support claims made about any cancer treatment, as lives are at stake. While it’s tempting to think that a cancer patient has nothing to lose by trying an alternative treatment, in fact, there are big risks. Taking medications outside of those recommended by your oncologist may have interactions and additional side-effects, so consult a medical professional before taking anything new.
Using cannabis oil as a means to treat or cure cancer is a topic of much online debate and the internet is full of people claiming that it has effectively helped to cure their cancer. We take a closer look at the evidence behind these claims.
Does the oral contraceptive pill decrease your risk of ovarian cancer?
Advice and support for if your cancer has returned.
However, while many of these studies show exciting early promise, killing cancer cells in a laboratory is far simpler than killing cancer cells in the human body. Until a cancer treatment has gone through the full stages of testing in animals and people, we cannot be certain that it works. Decades of cancer research has demonstrated that cancer is an incredibly complex and varied disease that varies from person to person and tumour to tumour. As a result, any claim that there could be a single cure for all cancers should be treated with a healthy dose of scepticism.
We explore the research into the link between oral contraceptive pill and a decreased risk of ovarian cancer
Cbd is only any good as a pain killer, some people have been using it for years me included..
Good luck with your treatment and best wishes for the future.
Ovarian cancer and CBD oil
1389 posts since
Hi Paul, Are you meaning to treat the cancer, or manage symptoms? Some people certainly swear by CBD for pain or chemotherapy induced nausea. Others I’ve spoken to don’t find it effective at all. It also has a huge variability in what dose can be effective and needs to be slowly increased over a few weeks. There are a few potential interactions with other medications so you would need to discuss with treating oncologist.
As far as any body knows no tests have been done to check on anything else. Thares also a risk of different side effects maybe some of them bad. Check with oncologist before trying.
The management of patients with LGSOC remains a challenge, particularly in the advanced stage and recurrent setting. The current standard of care remains platinum and taxane based combination chemotherapy, followed by maintenance hormonal therapy. Unfortunately, patients who progress have limited therapeutic options and are encouraged to consider clinical trials if available, as response rates to chemotherapy in the recurrent setting are less than 5% (Grisham and Iyer, 2018).
In July 2017, CT imaging was repeated and she was found to have a decrease in the size of the bilateral adnexal masses and mesenteric and pelvic lymphadenopathy, which was confirmed by clinical exam. Her mesenteric and omental carcinomatosis remained stable. Genomic profiling of her primary surgical specimen was ordered at this time and no molecular aberrations were identified. She was seen for follow up in September 2017, four months after starting initial treatment, and repeat imaging in November 2017 continued to show a dramatic reduction in her disease burden, with near complete resolution of all previously identified lesions ( Fig. 3 ). On her most recent interval assessment in December 2018 she continues to show a response to therapy. She is clinically asymptomatic with a performance status of 0, which is unchanged from her performance status at time of diagnosis.
In addition to standard treatments, an increasing proportion of patients are exploring and incorporating complimentary alternative medicine (CAM) for the management of their cancers. Use of CAM is common among gynecologic cancer patients, although many patients may not disclose use to their treating physician. Women who are older are more likely to use CAM either in conjunction with standard treatment or alone, as compared to their younger or male counterparts (Gansler et al., 2008). These therapies may or may not be recommended by their primary oncologist, and many have not been evaluated in a clinical trial setting.
An 81-year-old woman presented to her primary care physician with an umbilical mass that was suspected to be a hernia in March 2017. She was taken to the operating room in April 2017 for planned herniorrhaphy. The surgical findings were notable for a solid, peri-umbilical mass, as well as diffuse intra-abdominal nodularity. Final pathology of the resected umbilical lesion demonstrated a serous carcinoma, likely mullerian primary based on immunohistochemistry staining. Her Ca-125 was found to be elevated at 77.
In an effort to improve oncologic outcomes, investigators have attempted to capitalize on molecular aberrations identified in LGSOC specimens. Most recently, the utilization of MEK inhibitors have been explored due to noted activation of the mitogen-activate protein kinase (MAPK) pathway in LGSOC. A phase II trial evaluating Selumatib activity in women with recurrent LGSOC (GOG 0239) demonstrated a 15% overall response rate, catalyzing the development of phase III trials examining alternate agents in this setting (Farley et al., 2013). A phase III study evaluating Trametinib vs. physicians choice chemotherapy in patients with recurrent or progressive LGSOC (GOG-281) has closed to accrual and will help guide further management with these targeted agents. Furthermore, efforts to identify appropriate patient subsets based on molecular profiling are ongoing. In context of the above, optimal management of these relatively chemotherapy-resistant tumors due to their low-grade nature remains an active area of investigation.
After extensive counseling, the patient declined all interventions due to concerns regarding quality of life and treatment toxicity. She elected to pursue alternative therapy and started Laetrile tablets (500 mg orally four times per day) and cannabidiol (CBD) oil (1 drop sublingually each evening) in May 2017. Her Ca-125 level in May 2017 was 46, and after one month on the above regimen, her Ca-125 normalized to 22 ( Fig. 2 ).
Following the above surgery, she underwent diagnostic imaging, with computed tomography (CT) scan of the chest, abdomen and pelvis demonstrating multiple mesenteric soft tissue masses ranging from 7 mm to 7 cm and omental carcinomatosis. A 5.8 cm solid right adnexal mass and 3.3 cm solid left adnexal mass were also identified ( Fig. 1 ). Lymphadenopathy was noted along the left common iliac vessels and the left pelvic sidewall. She was subsequently referred to our practice for consultation and based on imaging and clinical examination, neoadjuvant carboplatin/paclitaxel with interval cytoreduction was recommended. She denied any known family history of cancer and BRCA 1 and 2 germline testing was negative. Her pathology was reviewed at our institution and confirmed to be LGSOC with low grade atypia and occasional psammoma bodies. The submitted tissue sample was estrogen and progesterone receptor positive.